Self-disintegrating protein-leaking microparticles for topical protein delivery
Year: 2025
Type: article
Abstract: Advanced drug delivery systems, if engineered to enhance drug stability and extend its kinetic bioavailability, are expected to expand the spectrum of local therapeutic approaches for dermatological conditions. In this context, the objective of this study was to explore whether artificial secretory granules, namely nontoxic, microscale granular Zn-assisted protein depots that leak the forming protein in a time-prolonged way, could be suited as functional agents in topical delivery. A model, recombinant form of the human fibroblast growth factor 2 (FGF-2), formulated as secretory granules, promoted efficient tissue repair and wound healing in a rat skin injury model faster than the natural repair process. The kinetic and histological analysis of FGF-2-treated wounds revealed that the package of the protein as secretory granules improves skin regeneration over the soluble version, and that it conduces to a more ordered construction of the extracellular matrix with limited risk of fibrosis. On the other hand, the addition of a claudin-binding peptide (c-CPE) as a fused protein segment slightly delays wound healing but offers functional and histological particularities that modulate the skin regeneration process. Altogether, the data presented here validates this endocrine-like protein drug delivery from synthetic disintegrating protein depots as a powerful and versatile platform for topical application in dermatological disorders.
Institutions: Universitat Autònoma de Barcelona, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red, Universidad Nacional de Córdoba, University of Naples Federico II, Josep Carreras Leukaemia Research Institute, Institut de Recerca Sant Pau, Consejo Nacional de Investigaciones Científicas y Técnicas
Language: English
Topic: Wound Healing and Treatments
Subfield: Rehabilitation
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,390
Funders: University of Alabama at Birmingham, International Centre for Theoretical Sciences, European Commission, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina, Universitat Autònoma de Barcelona, National Institutes of Health, University of California, San Francisco, Parker H. Petit Institute for Bioengineering and Bioscience, Agència de Gestió d'Ajuts Universitaris i de Recerca, Instituto de Salud Carlos III, European Regional Development Fund, Agencia Estatal de Investigación, National Institute of Allergy and Infectious Diseases, European Social Fund, Ministerio de Universidades
Awards: G110858599, G1525059614, G1899042073, G2262748287, G2645372123, ELIMINACIÓN SELECTIVA DE CÉLULAS MADRE DE CÁNCER DE COLON MEDIANTE NANOPARTÍCULAS INDUCTORAS DE PORO, INFLAMACIÓN CRÓNICA E IMMUNIDAD ANTINEOPLÁSICA (IMMUNO-FIRING), G3143460420, G3480869486, G3681454997, Eliminación selectiva de células madre metastásicas del cáncer colorrectal por bloqueo de la RNA polimerasa II., G4042783231, G425668148, G451917667, G5369293852, G5475273385, G5682902287, G5852091828, G5967599077, G6218905885, G6486171244, G6820597622, G6976177242, G7084143925, Conjugación dirigida de nanomedicinas proteicas inteligentes para la mejora de la terapia selectiva del cáncer metastasico de colon., G7241906850, G7604509605, G804926142, G8615798461, G9000187433, G935884346
OpenAlex ID: W4414224245